HEMOGENYX PHARMACEUTICALS PLC Logo

HEMOGENYX PHARMACEUTICALS PLC

Develops CAR-T therapies for blood cancers, autoimmune disorders, and viral infections.

HEMO | IL

Overview

Corporate Details

ISIN(s):
GB00BYX3WZ24
LEI:
2138008L93GYU5GN6179
Country:
United Kingdom
Address:
6TH FLOOR, 60 GRACECHURCH STREET, EC3V 0HR LONDON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Hemogenyx Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for life-threatening diseases. The company develops new medicines and treatments targeting blood diseases, autoimmune disorders, and viral infections. Its pipeline includes immunotherapy product candidates, such as CAR-T cell therapies, for the treatment of blood malignancies like acute myeloid leukemia (AML). Hemogenyx is dedicated to creating breakthrough treatments to address significant unmet medical needs, including improving the safety and efficacy of bone marrow transplantation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-23 08:00
Regulatory News Service
Hemogenyx Signs Letter of Intent
English 17.6 KB
2025-09-18 14:16
Major Shareholding Notification
Holding(s) in Company
English 60.2 KB
2025-09-17 08:00
Legal Proceedings Report
Third Patient Safety
English 16.5 KB
2025-09-11 08:00
Regulatory News Service
Invitation to Participate at DCNY Summit
English 11.6 KB
2025-09-08 08:00
Regulatory News Service
Manufacturing Partnership with Made Scientific
English 13.2 KB
2025-09-03 14:57
Share Issue/Capital Change
Exercise of Warrants and Issue of Equity
English 11.8 KB
2025-08-15 08:00
Regulatory News Service
Third Patient Treated with HG-CT-1 CAR-T Therapy
English 12.2 KB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 10.1 KB
2025-07-29 09:00
Share Issue/Capital Change
Placing to Raise £250,000 and Director’s Dealing
English 26.5 KB
2025-07-16 08:00
Regulatory News Service
Hemogenyx Awarded Grant
English 14.6 KB
2025-06-30 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 9.6 KB
2025-06-03 15:02
Director's Dealing
Placing to Raise £451,250 and Director’s Dealing
English 26.1 KB
2025-06-03 08:00
Legal Proceedings Report
Second Patient Passes Initial Safety Tests
English 14.9 KB
2025-05-31 12:30
Post-Annual General Meeting Information
Resolutions passed at Annual General Meeting of Hemogenyx Pharmaceuticals plc o…
English 33.9 KB
2025-05-29 15:06
Post-Annual General Meeting Information
Result of AGM
English 27.1 KB

Automate Your Workflow. Get a real-time feed of all HEMOGENYX PHARMACEUTICALS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for HEMOGENYX PHARMACEUTICALS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.